Science and Innovation: Alan Turing Institute

Baroness Morgan of Drefelin Excerpts

Monday 19th May 2025 Lords Chamber

[Lord Vallance of Balham (Lab)]

I thank the noble Baroness for her very important question. She may be aware that the final thing I did before leaving my job as the Government’s Chief Scientific Adviser was to commission work on the creative industries by the Council for Science and Technology, for exactly that reason. Most start-ups are populated not just by technicians or scientists; they have people from arts and humanities backgrounds as well. The business of where your science fits into society is incredibly important and requires people with a multitude of skills. Therefore, we will continue to support the arts and humanities for their own sake, and for the benefit they bring to the economy through creative industries and their contribution to science and technology companies.

[Baroness Morgan of Drefelin (Lab)]

My Lords, the life sciences sector plays a key role in promoting innovation in the UK, and we can all be very proud of the work that it does. One of the key factors in promoting an enhanced impact is the speed at which clinical trials can be accelerated. Can the Minister say a little bit more about what progress is being made? It is quite a complex challenge to speed up clinical trials, given all the regulation, but doing so has the huge benefit of creating more jobs, contributing to growth and helping patients access new and potentially more effective drugs.

[Lord Vallance of Balham (Lab)]

My noble friend is quite right that clinical trials are of huge importance and benefit healthcare just from the very fact that they take place in the healthcare system, irrespective of their outcome. Historically, we have been extremely good at clinical trials in this country. Indeed, during Covid, the world’s most important clinical trial took place here: the recovery study, which was the biggest, fastest and most important study and gave definitive results. However, it is also true that our performance in commercial clinical trials has deteriorated over the past few years. We are absolutely determined to return that to where it should be, and we will be clear in a very public way about the metrics and our progress against those, to make sure that we get back to where we belong.